O等位基因引起ABO基因型与表现型定型差异

保证输血时血清学方面的安全,首要的是对受血者与献血者ABO血型定型,血清学检查通常分两个步骤.正定型通常使用鼠源单克隆抗体检测红细胞表面是否存在A或B抗原.互补的实验即反定型,利用当红细胞上缺乏A或B抗原时,人群可天然产生相对应的抗体的原理,检测血清中是否存在抗-A或者抗-B抗体.确定了受血者红细胞表面的ABO抗原以及血浆中的抗体,便能确定血型,为其提供相合的血液.     

参三七皂苷Rg1预适应对5-氮胞苷诱导大鼠骨髓间充质干细胞向心肌细胞转化的干预

目的:用药物预适应方法进行干细胞诱导已有报道,本实验观察中药参三七皂苷Rg1对5-氮胞苷诱导大鼠骨髓间充质干细胞向心肌细胞转化中的作用。方法:实验于2003-01/05在南京医科大学药理教研室完成。①实验材料:清洁级SD大鼠8只。参三七皂苷Rg18mg,批号20021017,由云南省长春花生物制剂公司提供,加入不含胎牛血清的IMDM培养液10mL,调配成10-4mol/L溶液,4℃保存。5-氮胞苷(Sigma公司,批号021209)。②实验方法:贴壁法体外培养大鼠骨髓间充质干细胞。设立4组:空白对照组常规培养后进行无血清处理,每3d换液1次;5-氮胞苷单用组单纯以10μmol/L的5-氮胞苷进行处理,其终浓度为1×10-8moL/L,连续诱导15d;5-氮胞苷 参三七皂苷Rg1预适应组分别加入0.1,1μmol/L参三七皂苷Rg1培养液处理24h,再各以10μmol/L的5-氮胞苷进行诱导,其终浓度为1×10-8moL/L,连续诱导15d。③实验评估:取第2代骨髓间充质干细胞,绘制生长曲线并计算群体倍增时间。观察诱导后骨髓间充质干细胞的生长形态学特征和细胞超微结构变化。激光共聚焦显微镜测定细胞表面积变化和细胞内钙离子浓度。结果:①5-氮胞苷诱导后骨髓间充质干细胞的生长形态学特征和细胞超微结构变化:骨髓间质干细胞胞体逐渐增大并伸出细长突起,在突起末端出现分支,部分相邻细胞的突起连接成网,形态学上表现出向心肌细胞方向转化的特征。其超微结构呈梭形,有明显的肌丝,细胞核呈单椭圆形,位于细胞中央,间质干细胞形似心肌细胞。②参三七皂苷Rg1预适应对5-氮胞苷诱导的骨髓间充质干细胞增殖特性的影响:与5-氮胞苷单用组比较,5-氮胞苷 参三七皂苷Rg1预适应组从第3天开始细胞数明显增加,细胞生长曲线均无明显的生长平台期,达到高峰后细胞数开始减少。③参三七皂苷Rg1预适应对5-氮胞苷诱导的骨髓间充质干细胞表面积的影响:与空白对照组骨髓间充质干细胞表面积比较,5-氮胞苷单用组明显降低,0.1,1μmol/L参三七皂苷Rg1预适应则能显著升高5-氮胞苷诱导的骨髓间充质干细胞表面积(P<0.01)。④参三七皂苷Rg1对5-氮胞苷诱导的骨髓间充质干细胞内游离钙水平的影响:与空白对照组比较,5-氮胞苷诱导4周后骨髓间充质干细胞内游离Ca2 相对荧光强度均明显升高(t=6.72,P<0.01),且5-氮胞苷 1μmol/L参三七皂苷Rg1预适应组升高幅度大于5-氮胞苷单用组(t=3.13,P<0.05)。结论:①参三七皂苷Rg1预适应在体外可显著刺激5-氮胞苷诱导的鼠骨髓间充质干细胞向心肌细胞转化和增殖,改善细胞形态,刺激细胞内钙离子增加。②参三七皂苷Rg1与5-氮胞苷对骨髓间充质干细胞向心肌细胞定向分化产生协同效应。     

健康人群隐神经传导中远端和近端方法的比较

隐神经传导对隐、股神经损伤,腰丛病变和L3、L4神经根损伤具有诊断价值.在通过表面电极评估隐神经逆向传导中,有远端和近端两种方法.[收稿日期 2005-09-20     

自体干细胞移植治疗老年心肌梗死后心力衰竭

目的：实验以移植后3个月、6个月时间超声心动图客观指标评估了自体干细胞冠状动脉内移植治疗老龄心肌梗死后心力衰竭的效果和安全性。方法：选择2004—06／2006—06江苏省苏北人民医院心内科自愿接受干细胞移植的7例心肌梗死后心力衰竭患者，平均年龄69岁，心功能Ⅲ-Ⅳ级，左室射血分数〈50％。药物治疗基础上加用自体干细胞冠状动脉内移植治疗的方法，其中2例骨髓干细胞在体外扩增后获得，5例经粒细胞集落刺激因子皮下注射动员自体骨髓干细胞后分离外周血获得干细胞悬液。将采集的干细胞悬液经0ver-the-wire球囊导管中心腔注入梗死相关动脉。观察自体干细胞动员，培养，采集和回输过程中的不良反应。在移植前、移植后3月、6月应用超声心动图评价左室形态和心功能变化，室壁运动积分指数及6min步行距离。结果：7例患者均进入结果分析。移植3个月后，心功能得到改善，超声心动图检查左室收缩期内径及射血分数变化不大，6min步行距离有所提高，但差异无显著性（P〉0．05）。移植6个月后，患者心功能明显改善，超声心动图检查左室收缩期内径及射血分数和室壁运动积分均有明显提高（P〈0．05），6min步行距离也有明显提高（P〈0．05）。整个过程中未出现严重并发症。结论：自体干细胞冠状动脉内移植治疗老龄心肌梗死后心力衰竭，6个月时超声心动图客观指标评估能够改善患者心功能，且安全。     

The chasm of care: Where does the mental health nursing responsibility lie for the physical health care of people with severe mental illness?

The poor physical health of people with a severe mental illness is well documented and health professionals' attitudes, knowledge and skills are identified factors that impact on clients' access to care for their physical health needs. An evaluation was conducted to determine: (i) mental health nurses' attitudes and beliefs about providing physical health care; and, (ii) the effect that participant demographics may have on attitudes to providing physical health care. It was hypothesized that workplace culture would have the largest effect on attitudes. Nurses at three health services completed the “Mental health nurses' attitude towards the physical health care of people with severe and enduring mental illness survey” developed by Robson and Haddad (2012). The 28‐item survey measured: nurses' attitudes, confidence, identified barriers to providing care and attitudes towards clients smoking cigarettes. The findings demonstrated that workplace culture did influence the level of physical health care provided to clients. However, at the individual level, nurses remain divided and uncertain where their responsibilities lie. Nursing leadership can have a significant impact on improving clients' physical health outcomes. Education is required to raise awareness of the need to reduce cigarette smoking in this client population.     

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model

Introduction

New oral anticoagulants are effective alternatives to warfarin. However, no specific reversal agents are available for life-threatening bleeding or emergency surgery. Using a porcine model of trauma, this study assessed the ability of prothrombin complex concentrate (PCC), activated PCC (aPCC), recombinant FVIIa (rFVIIa) and a specific antidote to dabigatran (aDabi-Fab) to reverse the anticoagulant effects of dabigatran.

Methods

Dabigatran etexilate (DE) was given orally for 3 days (30 mg/kg bid) and intravenously on day 4 to achieve consistent, supratherapeutic concentrations of dabigatran. Blood samples were collected at baseline, after oral DE, after intravenous dabigatran, and 60 minutes post-injury. PCC (30 and 60 U/kg), aPCC (30 and 60 U/kg), rFVIIa (90 and 180 μg/kg) and antidote (60 and 120 mg/kg) were added to blood samples ex-vivo. Coagulation was assessed by thromboelastometry, global coagulation assays and diluted thrombin time.

Results

Plasma concentrations of dabigatran were 380 ± 106 ng/ml and 1423 ± 432 ng/ml after oral and intravenous administration, respectively, and all coagulation parameters were affected by dabigatran. Both PCCs and aDabi-Fab, but not rFVIIa, reversed the effects of dabigatran on thromboelastometry parameters and prothrombin time. In contrast, aPTT was only normalised by aDabi-Fab. Plasma concentration (activity) of dabigatran remained elevated after PCC and rFVIIa therapy, but was not measureable after aDabi-Fab.

Conclusion

In conclusion, PCC and aPCC were effective in reducing the anticoagulant effects of dabigatran under different conditions, while aDabi-Fab fully corrected all coagulation measures and decreased the plasma concentration of dabigatran below the limit of detection. No significant effects were observed with rFVIIa.     

Meropenem-RPX7009 Concentrations in Plasma,Epithelial Lining Fluid,and Alveolar Macrophages of Healthy Adult Subjects

The steady-state concentrations of meropenem and the β-lactamase inhibitor RPX7009 in plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations were obtained in 25 healthy, nonsmoking adult subjects. Subjects received a fixed combination of meropenem (2 g) and RPX7009 (2 g) administered every 8 h, as a 3-h intravenous infusion, for a total of three doses. A bronchoscopy and bronchoalveolar lavage were performed once in each subject at 1.5, 3.25, 4, 6, or 8 h after the start of the last infusion. Meropenem and RPX7009 achieved a similar time course and magnitude of concentrations in plasma and ELF. The mean pharmacokinetic parameters ± the standard deviations of meropenem and RPX7009 determined from serial plasma concentrations were as follows: C_max = 58.2 ± 10.8 and 59.0 ± 8.4 μg/ml, V_ss = 16.3 ± 2.6 and 17.6 ± 2.6 liters; CL = 11.1 ± 2.1 and 10.1 ± 1.9 liters/h, and t_1/2 = 1.03 ± 0.15 and 1.27 ± 0.21 h, respectively. The intrapulmonary penetrations of meropenem and RPX7009 were ca. 63 and 53%, respectively, based on the area under the concentration-time curve from 0 to 8 h (AUC_0–8) values of ELF and total plasma concentrations. When unbound plasma concentrations were considered, ELF penetrations were 65 and 79% for meropenem and RPX7009, respectively. Meropenem concentrations in AMs were below the quantitative limit of detection, whereas median concentrations of RPX7009 in AMs ranged from 2.35 to 6.94 μg/ml. The results from the present study lend support to exploring a fixed combination of meropenem (2 g) and RPX7009 (2 g) for the treatment of lower respiratory tract infections caused by meropenem-resistant Gram-negative pathogens susceptible to the combination of meropenem-RPX7009.     

急性缺血性卒中影像学检查的建议——美国心脏协会的科学声明（上）

卒中是一种常见、严重的疾病,仅美国每年的新发病例就高达795000例,并已成为全世界人类死亡和残疾的主要病因。10年前,重组型组织纤溶酶原激活剂（recombinant tissue plasminogen activator,rt—PA）被批准用于治疗急性缺血性卒中。rt—PA应用指南建议,应在卒中发病后3h内静脉给予rt—PA,给药前应行头部CT检查,排除颅内出血。     

急性缺血性卒中影像学检查的建议——美国心脏协会的科学声明（中）

2．3核磁共振血管成像（MRA） 2．3．1背景和方法：在头部MRI检查中常结合MRA,用于急性卒中患者病情评估以指导治疗决策的制定^[19]。日前,有几种不同的MRA技术用于脑血管成像,包括二维时间飞跃（timeof-flight,TOF）序列、三维TOF序列、